...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Clinical Outcomes Following Coronary Stenting in Japanese Patients Treated With and Without Proton Pump Inhibitor
【24h】

Clinical Outcomes Following Coronary Stenting in Japanese Patients Treated With and Without Proton Pump Inhibitor

机译：接受或不接受质子泵抑制剂治疗的日本患者冠状动脉支架术后的临床结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of this study was to examine the effect of proton-pump inhibitor (PPI) on clinical outcomes in Japanese patients who undergo coronary stent implantation. Methods and Results: A total of 1,270 patients (males 915, 69 years) were enrolled and dual antiplatelet therapy of aspirin and a thienopyridine derivative was prescribed (clopidogrel 630, ticlopidine 640). Patients were divided into 2 groups treated with or without PPI. PPI was administered in 331 cases (26%), and non-PPI in 939 (74%). There were no significant differences in cardiovascular death (PPI vs. non-PPI: 5 vs. 11 cases), nonfatal myocardial infarction (3 vs. 5), and stroke (3 vs. 16) between PPI and non-PPI groups, but the ratio of gastrointestinal events had a higher tendency in non-PPI group compared with PPI group (1 vs. 17, P=0.08). In subgroup analysis of patients taking clopidogrel, or patients with acute coronary syndrome, there was no significant difference in the ratio of cardiovascular events (7 vs. 16, 6 vs. 17, NS). The non-PPI group had a tendency of an increased risk of gastrointestinal events compared with the PPI group (0 vs. 9, P=0.06; 1 vs. 7, P=0.14). Conclusions: In contrast to the negative drug interaction of PPI reported elsewhere, in the present study the intake of PPI was not associated with an increased risk for adverse clinical outcomes in patients treated with stents. ( Circ J 2012; 76: 71-78)
机译：背景：本研究的目的是研究质子泵抑制剂（PPI）对日本冠状动脉支架置入患者临床预后的影响。方法和结果：共入组1270例患者（男性915岁，69岁），并开具阿司匹林和噻吩并吡啶衍生物（氯吡格雷630，噻氯匹定640）的双重抗血小板治疗。将患者分为两组，接受或不接受PPI治疗。 PPI给药331例（26％），非PPI 939例（74％）。 PPI组和非PPI组之间的​​心血管死亡（PPI与非PPI：5对11例），非致命性心肌梗塞（3对5）和中风（3对16）无显着差异，但是非PPI组的胃肠道事件发生率比PPI组高（1对17，P = 0.08）。在对服用氯吡格雷或急性冠脉综合征的患者进行的亚组分析中，心血管事件的发生率没有显着差异（7 vs. 16、6 vs. 17，NS）。与PPI组相比，非PPI组有增加胃肠道事件风险的趋势（0 vs. 9，P = 0.06; 1 vs. 7，P = 0.14）。结论：与其他地方报道的PPI的药物不良反应相反，在本研究中，PPI的摄入与支架治疗患者不良临床结局的风险增加无关。 （Circ J 2012; 76：71-78）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号